Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sierra Oncology Inc (SRRA)

Sierra Oncology Inc (SRRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 159,818
  • Shares Outstanding, K 11,041
  • Annual Sales, $ 0 K
  • Annual Income, $ -88,280 K
  • 60-Month Beta 1.12
  • Price/Sales 1,340.83
  • Price/Cash Flow N/A
  • Price/Book 1.38
Trade SRRA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/20
See More
  • Average Estimate -1.52
  • Number of Estimates 4
  • High Estimate -1.36
  • Low Estimate -1.94
  • Prior Year -2.67
  • Growth Rate Est. (year over year) +43.07%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.68 +7.75%
on 02/23/21
15.98 -7.79%
on 02/11/21
-0.93 (-5.93%)
since 01/26/21
3-Month
13.32 +10.66%
on 12/01/20
16.92 -12.88%
on 12/22/20
+0.08 (+0.55%)
since 11/25/20
52-Week
8.55 +72.50%
on 03/18/20
16.92 -12.88%
on 12/22/20
+1.79 (+13.82%)
since 02/26/20

Most Recent Stories

More News
Sierra Oncology Announces Presentation at LifeSci Partners Precision Oncology Day

, /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief...

SRRA : 14.74 (+1.83%)
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN MATEO, Calif., /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, granted a stock option...

SRRA : 14.74 (+1.83%)
Frazier Healthcare Partners Adds Highly Experienced Investor to Life Sciences Team

Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private biopharmaceutical...

AGN : 193.02 (+0.02%)
ASND : 154.97 (-2.33%)
KALV : 32.87 (-1.05%)
ACRS : 22.28 (+5.00%)
BHVN : 84.98 (+2.20%)
MNLO : 1.3500 (-2.17%)
SRRA : 14.74 (+1.83%)
BIOD : 0.65 (+6.56%)
RedHill's (RDHL) RHB-204 Gets FDA Fast Track Designation

RedHill (RDHL) gets Fast Track status from the FDA for the treatment of nontuberculous mycobacteria (NTM) disease.

UTHR : 167.54 (-0.75%)
BLRX : 3.09 (-4.33%)
RDHL : 9.50 (-4.43%)
SRRA : 14.74 (+1.83%)
Sierra Oncology to Present at H.C. Wainwright 2021 BioConnect Virtual Conference

, /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company on a quest to deliver targeted therapies that treat rare forms of cancer, today announced that President and Chief...

SRRA : 14.74 (+1.83%)
Altimmune (ALT) Begins Phase II Study for Chronic Hepatitis B

Altimmune (ALT) enrolls the first patient in a phase II study evaluating HepTcell for the treatment of patients with chronic hepatitis B. Shares rise.

IRWD : 9.23 (+2.10%)
BLRX : 3.09 (-4.33%)
ALT : 15.94 (-7.33%)
SRRA : 14.74 (+1.83%)
Nektar (NKTR) Begins Dosing in NKTR-255 Study for Two Cancers

Nektar (NKTR) doses the first patient in a phase I/II study on NKTR-255 in combination with Erbitux for treating head and neck squamous cell carcinoma or colorectal cancer. Shares up.

LLY : 204.89 (+0.52%)
BLRX : 3.09 (-4.33%)
NKTR : 22.69 (+1.11%)
SRRA : 14.74 (+1.83%)
Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH

Sierra Oncology to Host KOL Panel Event to Discuss Updated Phase 3 Myelofibrosis Data Presented at ASH

SRRA : 14.74 (+1.83%)
Sierra Oncology Announces Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

VANCOUVER, BC, /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel...

SRRA : 14.74 (+1.83%)
Sierra Oncology to Present at 2020 Jefferies Virtual London Healthcare Conference

, /PRNewswire/ - Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may...

SRRA : 14.74 (+1.83%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sierra Oncology, Inc. is a clinical-stage drug development company. It develops and markets drugs for the treatment of cancer. The product pipeline consists of SRA737 and SRA141. SRA737 is an orally bioavailable small molecule inhibitor of Checkpoint kinase 1, a key cell cycle checkpoint and central...

See More

Key Turning Points

3rd Resistance Point 15.14
2nd Resistance Point 14.85
1st Resistance Point 14.66
Last Price 14.74
1st Support Level 14.18
2nd Support Level 13.89
3rd Support Level 13.70

See More

52-Week High 16.92
Last Price 14.74
Fibonacci 61.8% 13.72
Fibonacci 50% 12.73
Fibonacci 38.2% 11.74
52-Week Low 8.55

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar